健康2026/09/23@HealthDesk
Abbott Settles Gill Case and 2,000 NEC Formula Claims for $670M
Abbott Laboratories…Abbott Labs, 100, Abbott Park Road, Illinois, 60064, United States
开始于 2026/08/20已确认可信度 86%34天前The release is datelined "ABBOTT PARK, Ill., Aug. 20, 2026" and the 8-K says "On August 20, 2026 ... Abbott entered into agreements to resolve the Gill lawsuit".^[1]
Abbott agreed with three law firms to pay about $670 million to settle the Gill case, a $495 million St. Louis jury award, and NEC claims for about 2,000 other preterm infants fed its specialty formulas. About 1,700 lawsuits covering some 12,700 infants remain.
$670M
0.81
司法2026/09/23@LawDesk
Baltimore Jury Orders J&J to Pay $1.56 Billion Over Baby Powder Cancer
Clarence M. Mitchell Jr. Courthouse, 100 North Calvert Street, Baltimore, Maryland 21202, United States
开始于 2025/12/22已确认可信度 81%275天前The Baltimore Banner's report of Tuesday 23 December 2025 says "The jury returned the verdict in favor of Cherie Craft ... on Monday in Baltimore Circuit Court", i.e. Monday 22 December 2025 (Bloomberg: "Jurors in state court in Baltimore late Monday"); no time of day is reported, so the pin is all day.^[1]
A Baltimore City jury awarded Cherie Craft $59.84 million in compensatory and $1.5 billion in punitive damages, finding J&J's talc baby powder exposed her to the asbestos behind her peritoneal mesothelioma - the largest talc verdict for a single plaintiff. J&J said it would appeal.
$1.6B
0.66
法律2026/09/23@HealthDesk
J&J Proposes $5.5 Billion Deal to Settle 76,000 Ovarian Cancer Talc Claims
Johnson & Johnson…Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United States
开始于 2026/07/27 22:15已确认可信度 82%58天前J&J's release is datelined "New Brunswick, N.J. - JULY 27, 2026 - Johnson & Johnson (NYSE: JNJ^[1]) ... today announced", and the copy filed as Exhibit 99.1 to its 8-K is marked "FOR RELEASE AT 6:15PM ET", 22:15 UTC in EDT.
Johnson & Johnson announced a proposed resolution of its remaining ovarian talc litigation, about 76,000 claims, with a $5.5 billion commitment paid per claim - no more than $3 billion in 2027 and nothing more before 2028 - if at least 95% of claimants take part.
$5.5B
0.66
健康2026/09/23@HealthDesk
Abbott Agrees to Buy Exact Sciences for $21 Billion
Abbott Laboratories…Abbott Labs, 100, Abbott Park Road, Illinois, 60064, United States
开始于 2025/11/20已确认可信度 86%307天前The release is datelined "ABBOTT PARK, Ill., and MADISON, Wis., Nov. 20, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) and Exact Sciences (NASDAQ: EXAS) today announced a definitive agreement".^[1]
Abbott agreed to buy Cologuard maker Exact Sciences for $105 a share in cash, a total equity value of about $21 billion, to enter cancer screening and precision oncology diagnostics.
$21B
0.62
健康2026/09/23@HealthDesk
FDA Authorizes Abbott's Libre Duo Glucose-Ketone Sensor
Abbott Laboratories…1360 South Loop Road, Alameda, Alameda County, California, 94502, United States
开始于 2026/08/25已确认可信度 87%29天前The release is datelined "ABBOTT PARK, Ill., Aug. 25, 2026" and says Abbott "today announced U.S. Food and Drug Administration (FDA^[2][3]) authorization of its Libre Duo 10 Day system"; the FDA's De Novo record gives the same decision date, 08/25/2026.
The FDA authorized Abbott's Libre Duo 10 Day, the first wearable to continuously track both glucose and ketones, which alerts people with diabetes aged 2 and older to rising ketones before diabetic ketoacidosis.
0.61
健康2026/09/23@HealthDesk
J&J Signs a Drug-Pricing Deal With Trump and Joins TrumpRx
Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United StatesJohnson & Johnson…
开始于 2026/01/08已确认可信度 86%258天前J&J's release is datelined "New Brunswick, N.J. – JANUARY 8, 2026" and says the company "today announced a voluntary agreement with the Trump Administration"; coverage followed on 9 January.^[1]
Johnson & Johnson signed a voluntary most-favored-nation drug-pricing agreement with the Trump administration, selling medicines through TrumpRx.gov and to Medicaid at prices comparable to other developed countries in exchange for an exemption from pharmaceutical tariffs, and announced two new US plants in Pennsylvania and North Carolina.
0.60
健康2026/09/23@HealthDesk
Abbott Reports Q2 2026 Results and Raises Full-Year EPS Guidance
Abbott Laboratories…Abbott Labs, 100, Abbott Park Road, Illinois, 60064, United States
开始于 2026/07/16 13:00已确认可信度 86%69天前The release, datelined "ABBOTT^[5] PARK, Ill., July 16, 2026", says "Abbott will live-webcast its second-quarter earnings conference call ... at 8 a.m. Central time today", so the pin is 8 a.m. CDT (13:00 UTC) on 16 July 2026.
Abbott posted second-quarter sales of $12.59 billion, up 13.0% reported and 4.8% comparable, and adjusted EPS of $1.31, and raised its 2026 adjusted EPS guidance to $5.45 to $5.60.
0.60
健康2026/09/23@HealthDesk
雅培完成对Exact Sciences的收购
Abbott Laboratories…Abbott Labs, 100, Abbott Park Road, Illinois, 60064, United States
开始于 2026/03/23已确认可信度 87%184天前新闻稿标注发稿地和日期为“伊利诺伊州雅培园区，2026年3月23日／美通社／——雅培（纽约证券交易所代码：ABT）今日宣布已完成对Exact Sciences的收购”。^[1]
雅培以每股105美元现金完成对Cologuard生产商Exact Sciences的收购，后者成为雅培的全资子公司；Exact Sciences股票于3月20日在纳斯达克最后一个交易日交易。
0.59
健康2026/09/23@HealthDesk
FDA Approves Abbott's TactiFlex Duo Ablation Catheter
Abbott Laboratories…Abbott Labs, 100, Abbott Park Road, Illinois, 60064, United States
开始于 2026/09/08已确认可信度 86%15天前The release is datelined "ABBOTT PARK, Ill., Sept. 8, 2026" and says Abbott "announced today it has received U.S. Food and Drug Administration (FDA^[3]) approval" (the FDA's record gives a decision date of 09/04/2026).
The FDA approved Abbott's TactiFlex Duo, a catheter that can deliver pulsed field ablation, radiofrequency energy or both in one procedure to treat complex atrial fibrillation. The approval rested on the FlexPulse IDE study.
0.59
健康2026/09/23@HealthDesk
Abbott Corrects FreeStyle Libre 3 Sensors Over False Low Readings
Abbott Laboratories…Abbott Labs, 100, Abbott Park Road, Illinois, 60064, United States
开始于 2025/11/24已确认可信度 88%303天前Abbott's release is datelined "ABBOTT PARK, Ill., Nov. 24, 2025 — Abbott has initiated a medical device correction", and the FDA^[4] recall page says "On November 24, 2025, Abbott Diabetes Care sent all affected customers a letter".
Abbott began a medical device correction for about 3 million FreeStyle Libre 3 and Libre 3 Plus sensors in the U.S. after internal testing found some give incorrect low glucose readings, an issue it linked to 736 severe adverse events and seven deaths worldwide. The FDA later made it a Class I recall.
0.59
健康2026/09/23@HealthDesk
Lilly Agrees to Acquire Centessa for Up to $7.8 Billion
Eli Lilly…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
开始于 2026/03/31已确认可信度 87%176天前The joint release is datelined "INDIANAPOLIS and BOSTON and LONDON, March 31, 2026" and says the companies "today announced a definitive agreement for Lilly to acquire Centessa".^[1]
Lilly agrees to buy Centessa Pharmaceuticals, maker of the orexin agonist cleminorexton for narcolepsy, for $38 a share in cash (about $6.3 billion) plus a CVR worth up to $1.5 billion more; the deal closed on 24 June 2026.
$7.8B
0.59
司法2026/09/23@LawDesk
Judge Approves the DOJ's HPE-Juniper Settlement Over States' Objections
Robert F. Peckham United States Courthouse and Federal Building, 280 South 1st Street, San Jose, California 95113, United States
开始于 2026/08/12已确认可信度 85%42天前The order granting the motion for entry of final judgment (Case 5:25-cv-00951-PCP, Document 482) is 'Filed 08/12/26' and signed 'Dated: August 12, 2026' by P. Casey Pitts; no time is given, so it is an all-day date.^[1]
Judge P. Casey Pitts entered the consent decree clearing HPE's Juniper Networks deal in a 41-page order that found DOJ leadership overrode its own antitrust staff, but held that 12 states and DC had not shown the Instant On sale and Mist source-code licence were against the public interest.
0.58

The release is datelined "ABBOTT PARK, Ill., Sept. 14, 2026" and says Abbott "has reached an agreement"; the DOJ release is dated Monday, September 14, 2026.^[1]

开始: 2026年9月14日可信度 90%来自来源

Abbott Settles DOJ Infant Formula Claims for $385 Million

Abbott will pay about $385 million ($384,999,040) to resolve Justice Department, state and whistleblower claims over powdered infant formula made at its Sturgis, Michigan, plant, the site of the 2022 recall. Abbott admits no liability, and the government has closed its criminal investigation.

Abbott will pay a total of $385 million to resolve the Department of Justice investigation and lawsuit, plus suits by certain relators and several state Attorneys General, over its manufacturing and 2022 recall of powdered infant formula at its Sturgis, Mich., facility; the settlement does not represent any finding of fault or liability, and the government has closed its criminal investigation^[1]
The Justice Department puts the payment at $384,999,040 to resolve allegations that Abbott caused false claims to federal and state programs between 1 January 2018 and 31 December 2022 for formula and nutritional therapy products made at Sturgis, Michigan, and Casa Grande, Arizona: $348,700,868 to the United States under the False Claims Act and $36,298,172 to states for Medicaid and WIC claims^[3]
The complaint alleged recurring roof leaks over equipment at Sturgis, spray dryers kept running despite documented cracks and pits, and that in some instances Abbott failed to disclose micro contamination test results when the FDA asked for them during its 2019 and 2022 inspections^[3]
Former Abbott employees Scott Millard, Kristine Cooper and Loren Cooper, who brought the qui tam suit in the Western District of Michigan (No. 1:22-cv-994) on 24 October 2022, receive $69 million of the federal share; the United States filed its complaint in intervention on 13 November 2025^[3][4]
The settlement agreement is a compromise of disputed claims, not an admission of facts or liability, and Abbott denies the allegations^[4]
The FDA's 2022 inspection led Abbott to shut the plant, the country's largest formula factory, sparking a nationwide shortage; the plant closed in February 2022 and reopened by June, and Abbott later entered a consent decree giving the FDA oversight of Sturgis for five years^[2][5]

@HealthDesk

价格 $385M

参考资料 5可信度 88%

第一项始终是图钉的来源。总体可信度是各份资料对上方所用开始和结束时间支持程度的加权平均；资料每比最新的一份旧 180 天，权重减半。

[1]90%
abbott.mediaroom.com/2026-09-14-Abbott-reaches-agreement-with-Department-of-Justice-to-resolve-claims-relating-to-2022-infant-formula-recall
abbott.mediaroom.com· 发布于 2026年9月23日· 开始 2026年9月14日 ✓· 占评分 21%
The release is datelined "ABBOTT PARK, Ill., Sept. 14, 2026" and says Abbott "has reached an agreement"; the DOJ release is dated Monday, September 14, 2026.
[2]80%
Abbott to Pay $385 Million to End US Claims Over Infant Formula
claimsjournal.com· 发表于 2026年9月15日· 占评分 20%
Bloomberg report carried by Claims Journal: the settlement terms, the 2022 FDA inspection that sparked the shortage and the five-year consent decree.
[3]95%
Abbott Agrees to Pay Over $384M to Settle Allegations Related to Contaminated Infant Formula
justice.gov· 发表于 2026年9月14日· 占评分 20%
The Justice^[4] Department's own release: $384,999,040 settlement, the $348.7M federal and $36.3M state split, the Sturgis allegations and the $69M relator share.
[4]90%
Settlement Agreement: United States, Abbott Laboratories and relators (No. 1:22-cv-994, W.D. Mich.)
justice.gov· 发表于 2026年9月14日· 占评分 20%
The signed settlement agreement (dated 9/11-9/14/2026) linked from the DOJ release: case history, the $384,999,040.12 settlement amount and the no-admission clause.^[1]
[5]85%
Abbott agrees to settlement over closure of largest baby formula plant in the US
abcnews.com· 发表于 2026年9月14日· 占评分 20%
AP wire story on ABC News: $385M to resolve the Sturgis claims, the 2022 shutdown and shortage, and the closed criminal investigation.

建议更正

有遗漏或错误吗？用你自己的话说明：能佐证此图钉的链接、不同的开始或结束日期及理由，或缺失、有误的信息。AI 会对照此图钉的来源进行核实，搜索更好的来源，并添加任何支持你说法的页面。图钉自身的来源仍然最重要。

串

回应这个图钉

1Abbott Settles DOJ Infant Formula Claims for $385 Million开始时为 US$103.09

健康2026/09/23@HealthDesk
Abbott Settles Gill Case and 2,000 NEC Formula Claims for $670M
Abbott Laboratories…Abbott Labs, 100, Abbott Park Road, Illinois, 60064, United States
开始于 2026/08/20已确认可信度 86%34天前The release is datelined "ABBOTT PARK, Ill., Aug. 20, 2026" and the 8-K says "On August 20, 2026 ... Abbott entered into agreements to resolve the Gill lawsuit".^[1]
Abbott agreed with three law firms to pay about $670 million to settle the Gill case, a $495 million St. Louis jury award, and NEC claims for about 2,000 other preterm infants fed its specialty formulas. About 1,700 lawsuits covering some 12,700 infants remain.
$670M
0.81
司法2026/09/23@LawDesk
Baltimore Jury Orders J&J to Pay $1.56 Billion Over Baby Powder Cancer
Clarence M. Mitchell Jr. Courthouse, 100 North Calvert Street, Baltimore, Maryland 21202, United States
开始于 2025/12/22已确认可信度 81%275天前The Baltimore Banner's report of Tuesday 23 December 2025 says "The jury returned the verdict in favor of Cherie Craft ... on Monday in Baltimore Circuit Court", i.e. Monday 22 December 2025 (Bloomberg: "Jurors in state court in Baltimore late Monday"); no time of day is reported, so the pin is all day.^[1]
A Baltimore City jury awarded Cherie Craft $59.84 million in compensatory and $1.5 billion in punitive damages, finding J&J's talc baby powder exposed her to the asbestos behind her peritoneal mesothelioma - the largest talc verdict for a single plaintiff. J&J said it would appeal.
$1.6B
0.66
法律2026/09/23@HealthDesk
J&J Proposes $5.5 Billion Deal to Settle 76,000 Ovarian Cancer Talc Claims
Johnson & Johnson…Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United States
开始于 2026/07/27 22:15已确认可信度 82%58天前J&J's release is datelined "New Brunswick, N.J. - JULY 27, 2026 - Johnson & Johnson (NYSE: JNJ^[1]) ... today announced", and the copy filed as Exhibit 99.1 to its 8-K is marked "FOR RELEASE AT 6:15PM ET", 22:15 UTC in EDT.
Johnson & Johnson announced a proposed resolution of its remaining ovarian talc litigation, about 76,000 claims, with a $5.5 billion commitment paid per claim - no more than $3 billion in 2027 and nothing more before 2028 - if at least 95% of claimants take part.
$5.5B
0.66
健康2026/09/23@HealthDesk
Abbott Agrees to Buy Exact Sciences for $21 Billion
Abbott Laboratories…Abbott Labs, 100, Abbott Park Road, Illinois, 60064, United States
开始于 2025/11/20已确认可信度 86%307天前The release is datelined "ABBOTT PARK, Ill., and MADISON, Wis., Nov. 20, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) and Exact Sciences (NASDAQ: EXAS) today announced a definitive agreement".^[1]
Abbott agreed to buy Cologuard maker Exact Sciences for $105 a share in cash, a total equity value of about $21 billion, to enter cancer screening and precision oncology diagnostics.
$21B
0.62
健康2026/09/23@HealthDesk
FDA Authorizes Abbott's Libre Duo Glucose-Ketone Sensor
Abbott Laboratories…1360 South Loop Road, Alameda, Alameda County, California, 94502, United States
开始于 2026/08/25已确认可信度 87%29天前The release is datelined "ABBOTT PARK, Ill., Aug. 25, 2026" and says Abbott "today announced U.S. Food and Drug Administration (FDA^[2][3]) authorization of its Libre Duo 10 Day system"; the FDA's De Novo record gives the same decision date, 08/25/2026.
The FDA authorized Abbott's Libre Duo 10 Day, the first wearable to continuously track both glucose and ketones, which alerts people with diabetes aged 2 and older to rising ketones before diabetic ketoacidosis.
0.61
健康2026/09/23@HealthDesk
J&J Signs a Drug-Pricing Deal With Trump and Joins TrumpRx
Johnson & Johnson World Headquarters, 1 Johnson and Johnson Plaza, New Brunswick, New Jersey 08933, United StatesJohnson & Johnson…
开始于 2026/01/08已确认可信度 86%258天前J&J's release is datelined "New Brunswick, N.J. – JANUARY 8, 2026" and says the company "today announced a voluntary agreement with the Trump Administration"; coverage followed on 9 January.^[1]
Johnson & Johnson signed a voluntary most-favored-nation drug-pricing agreement with the Trump administration, selling medicines through TrumpRx.gov and to Medicaid at prices comparable to other developed countries in exchange for an exemption from pharmaceutical tariffs, and announced two new US plants in Pennsylvania and North Carolina.
0.60
健康2026/09/23@HealthDesk
Abbott Reports Q2 2026 Results and Raises Full-Year EPS Guidance
Abbott Laboratories…Abbott Labs, 100, Abbott Park Road, Illinois, 60064, United States
开始于 2026/07/16 13:00已确认可信度 86%69天前The release, datelined "ABBOTT^[5] PARK, Ill., July 16, 2026", says "Abbott will live-webcast its second-quarter earnings conference call ... at 8 a.m. Central time today", so the pin is 8 a.m. CDT (13:00 UTC) on 16 July 2026.
Abbott posted second-quarter sales of $12.59 billion, up 13.0% reported and 4.8% comparable, and adjusted EPS of $1.31, and raised its 2026 adjusted EPS guidance to $5.45 to $5.60.
0.60
健康2026/09/23@HealthDesk
雅培完成对Exact Sciences的收购
Abbott Laboratories…Abbott Labs, 100, Abbott Park Road, Illinois, 60064, United States
开始于 2026/03/23已确认可信度 87%184天前新闻稿标注发稿地和日期为“伊利诺伊州雅培园区，2026年3月23日／美通社／——雅培（纽约证券交易所代码：ABT）今日宣布已完成对Exact Sciences的收购”。^[1]
雅培以每股105美元现金完成对Cologuard生产商Exact Sciences的收购，后者成为雅培的全资子公司；Exact Sciences股票于3月20日在纳斯达克最后一个交易日交易。
0.59
健康2026/09/23@HealthDesk
FDA Approves Abbott's TactiFlex Duo Ablation Catheter
Abbott Laboratories…Abbott Labs, 100, Abbott Park Road, Illinois, 60064, United States
开始于 2026/09/08已确认可信度 86%15天前The release is datelined "ABBOTT PARK, Ill., Sept. 8, 2026" and says Abbott "announced today it has received U.S. Food and Drug Administration (FDA^[3]) approval" (the FDA's record gives a decision date of 09/04/2026).
The FDA approved Abbott's TactiFlex Duo, a catheter that can deliver pulsed field ablation, radiofrequency energy or both in one procedure to treat complex atrial fibrillation. The approval rested on the FlexPulse IDE study.
0.59
健康2026/09/23@HealthDesk
Abbott Corrects FreeStyle Libre 3 Sensors Over False Low Readings
Abbott Laboratories…Abbott Labs, 100, Abbott Park Road, Illinois, 60064, United States
开始于 2025/11/24已确认可信度 88%303天前Abbott's release is datelined "ABBOTT PARK, Ill., Nov. 24, 2025 — Abbott has initiated a medical device correction", and the FDA^[4] recall page says "On November 24, 2025, Abbott Diabetes Care sent all affected customers a letter".
Abbott began a medical device correction for about 3 million FreeStyle Libre 3 and Libre 3 Plus sensors in the U.S. after internal testing found some give incorrect low glucose readings, an issue it linked to 736 severe adverse events and seven deaths worldwide. The FDA later made it a Class I recall.
0.59
健康2026/09/23@HealthDesk
Lilly Agrees to Acquire Centessa for Up to $7.8 Billion
Eli Lilly…Eli Lilly and Company Corporate Center, East McCarty Street, Indianapolis, Indiana 46206, United States
开始于 2026/03/31已确认可信度 87%176天前The joint release is datelined "INDIANAPOLIS and BOSTON and LONDON, March 31, 2026" and says the companies "today announced a definitive agreement for Lilly to acquire Centessa".^[1]
Lilly agrees to buy Centessa Pharmaceuticals, maker of the orexin agonist cleminorexton for narcolepsy, for $38 a share in cash (about $6.3 billion) plus a CVR worth up to $1.5 billion more; the deal closed on 24 June 2026.
$7.8B
0.59
司法2026/09/23@LawDesk
Judge Approves the DOJ's HPE-Juniper Settlement Over States' Objections
Robert F. Peckham United States Courthouse and Federal Building, 280 South 1st Street, San Jose, California 95113, United States
开始于 2026/08/12已确认可信度 85%42天前The order granting the motion for entry of final judgment (Case 5:25-cv-00951-PCP, Document 482) is 'Filed 08/12/26' and signed 'Dated: August 12, 2026' by P. Casey Pitts; no time is given, so it is an all-day date.^[1]
Judge P. Casey Pitts entered the consent decree clearing HPE's Juniper Networks deal in a 41-page order that found DOJ leadership overrode its own antitrust staff, but held that 12 states and DC had not shown the Instant On sale and Mist source-code licence were against the public interest.
0.58

相似图钉

参考资料 5可信度 88%

建议更正

评论

串

相似图钉